氨丙嗪 | 58-37-7

• 物质功能分类: 原料药 - 呼吸系统用药 - 平喘药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 氨丙嗪
• 中文别名: N,N,N',N'-四甲基-3-(10H-吩噻嗪-10-基)-1,2-丙二胺；氨基普马嗪；氨基丙嗪；N,N,N",N"-四甲基-3-(10H-吩噻嗪-10-基)-1,2-丙二胺；氨丙嗪; N,N,N',N'-四甲基-3-(10H-吩噻嗪-10-基)-1,2-丙二胺
• 英文名称: Proquamezin
• 英文别名: 10-[2,3-bis(dimethylamino)propyl]phenothiazine；aminopromazine；tetra-N-methyl-3-phenothiazin-10-yl-propane-1,2-diamine；tetra-N-methyl-1-phenothiazin-10-ylmethyl-ethanediyldiamine；Tetra-N-methyl-1-phenothiazin-10-ylmethyl-aethandiyldiamin；10-(2.3-Bis-dimethylamino-propyl)-phenthiazin.；1-N,1-N,2-N,2-N-tetramethyl-3-phenothiazin-10-ylpropane-1,2-diamine
• CAS: 58-37-7
• 化学式: C₁₉H₂₅N₃S
• 分子量: 327.494
• InChiKey: YZQNFFLGIYEXMM-UHFFFAOYSA-N

物化性质

• 保留指数：
  2434;2414.3

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  氯化铑(三水) 、 氨丙嗪 以 乙醇 为溶剂， 生成 rhodium (II, III) (aminopromazine)2 Cl8
  参考文献：
  名称：

  Keshavan, B.; Janardhan, R., Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical and Analytical, 1988, vol. 27, # 6, p. 547 - 549

  摘要：

  DOI：
• 作为产物：
  描述：

  10-[2,3-bis(dimethylamino)-propyl]phenothiazine fumarate 在 potassium metaperiodate 、 磷酸 、 硫酸 作用下， 以 水 为溶剂， 生成 氨丙嗪
  参考文献：
  名称：

  Kuzmicka, L.; Puzanowska-Tarasiewicz, H.; Tarasiewicz, M., Pharmazie, 1988, vol. 43, # 4, p. 288 - 289

  摘要：

  DOI：

文献信息

• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• Cross-linkable phosphonate-containing supramolecular complexes and their use for delivery of therapeutic and diagnostic agents
  申请人：——

  公开号：US20030224038A1

  公开（公告）日：2003-12-04

  Cross-linkable, phosphonate containing supramoleuclar aggregates are disclosed, which may be used to advantage, for example, as drug delivery vehicles for the treatment of bone-related disorders.

  公开了含有交联性、膦酸盐的超分子聚集体，可以用作药物传递载体，例如用于治疗与骨相关的疾病。
• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Glucuronidated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014734A1

  公开（公告）日：2007-01-18

  This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol and/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also provides methods of treating and/or preventing vascular diseases, by administering at least one glucuronidated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one glucuronidated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  这项发明提供了葡萄糖醛酸化的尼布ivolol代谢物以及用于治疗心血管疾病的葡萄糖醛酸化的尼布ivolol代谢物的制药组合物。此外，该发明还提供了包含尼布ivolol和/或至少一种尼布ivolol的葡萄糖醛酸化代谢物和/或至少一种其他活性化合物的药用可接受载体的组合物。该发明还提供了通过向受影响血管疾病的靶位点投与至少一种能释放治疗有效量一氧化氮的尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防血管疾病的方法。此外，该发明旨在通过投与至少一种尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防偏头痛。该发明还可与代谢综合征紊乱的单一治疗或联合治疗一起使用。
• Process for removing metals from liquids
  申请人：——

  公开号：US20040170547A1

  公开（公告）日：2004-09-02

  A process is provided for removing one or more metals from liquids. Also provided is a process for the synthesis of aP2 inhibiting compounds having the formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 , HET, and X-Z are as described herein, which process comprising the step of removing one or more metals from a solution of the compound of formula I or an intermediate or precursor thereof. The processes for removing metal comprise the step of contacting the liquid with a solid extractant comprising a metal-binding functionality.

  提供了一种从液体中去除一种或多种金属的过程。还提供了一种合成具有公式（I）1的aP2抑制化合物的过程，其中R1、R2、R3、R4、HET和X-Z如本文所述，该过程包括从公式I化合物或其中间体或前体的溶液中去除一种或多种金属的步骤。去除金属的过程包括将液体与具有金属结合功能的固体萃取剂接触的步骤。

表征谱图